Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)

NCT06637345 is registered in ClinicalTrials.gov with Centro di Riferimento Oncologico - Aviano as lead sponsor.

NCT NCT06637345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06637345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of Prognostic and Predictive Biomarkers of Toxicity in Patients With Malignant Pleural Mesothelioma and Treated With High Doses of Radiotherapy (MESORTIBO)
Lead sponsor
Centro di Riferimento Oncologico - Aviano
Phase
Observational
Overall status
Recruiting
Start date
March 15, 2024
Completion date
March 15, 2027
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pleural mesothelioma malignant